Project Grant R43GM142408

Award Date 9/15/21
Completion Date 12/14/22
Dollars Obligated $905K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Science Foundation (NSF) Division of Integrative Organismal Systems awarded a $299,983 Project Grant to North Carolina State University (NCSU) under the agency's Biological Sciences program (CFDA 47.074). The objective of this 2-year grant is to develop a new biotechnology called RIBOPI that will enable efficient, scalable, and cost-effective quantification of gene-specific translation regulation. RIBOPI aims to make translation regulation analysis as accessible as RNA sequencing...
This Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172) provides $215,088 to Directseq Biosciences, Inc. to develop and test an "Exhaustive De Novo Sequencing of Every RNA in a Sample by a Layer-by-Layer Mass Spectrometry Ladder Intensity Approach." The project aims to create a comprehensive RNA sequencing and modification profiling method that can identify and sequence all RNA species in a sample...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), aims to develop an all-in-one platform for the intracellular overproduction of long, single-strand mRNA. The $300,518 award to E&E Bioclub LLC in Indianapolis, IN seeks to overcome challenges with current mRNA manufacturing methods by exploring combinatorial approaches, including host cell engineering, target RNA design, and a...
The National Institute of General Medical Sciences (NIGMS) awarded a $307,257 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Sxrna Technologies, Inc. The grant aims to develop a rapid cloning technology called "SXRNA-SELECT" that will decrease the time required to clone mammalian cells and increase protein yields for biologics production. The key objectives are to: 1) optimize the protocol for simultaneous delivery of plasmids and SXRNA-bait, 2)...
This Project Grant award from the National Institutes of Health's National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) provides $406,500 to Directseq Biosciences, Inc. to advance their next-generation mass spectrometry-based sequencing (NGMS-SEQ) methods for high-throughput direct sequencing and quantitative mapping of RNA modifications. The key objectives are to: 1) enhance NGMS-SEQ techniques to enable direct sequencing of various tRNA samples, including...
This $256,000 National Science Foundation Engineering grant supports the development of an easy RNA adenylation method for deep sequencing of picogram RNA samples with high resolution. Specifically, Ezrabio Inc. will develop a versatile and cost-effective library construction technology that enables protein translation monitoring on a variety of biological samples. The proposed technology relies on a novel enzyme system capable of 5' adenylation and 3' polyadenylation of RNA fragments to...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant (CFDA 93.859 - Biomedical Research and Research Training) to Dotquant LLC, a for-profit biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. This innovation aims to drastically improve the affordability of current and future RNA drugs by combining the benefits of wild-type T7 RNA polymerase's high efficiency and...
The National Human Genome Research Institute (NHGRI), through its Human Genome Research program (CFDA 93.172), has awarded a $352,929 Project Grant to Ribo-Therapeutics LLC to develop and validate a novel platform for the enrichment and profiling of circular RNAs (circRNAs). The goal is to create a "quick, robust, and unbiased" technology for isolating and characterizing the full repertoire of circRNAs, which have been implicated in various diseases but are challenging to study with...
This $350,000 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under the 93.350 CFDA program, supports the development of the Codomax EPI-MAX platform. This integrated omics and computational technology leverages cellular stress responses to enhance the production of difficult-to-express therapeutic proteins, with a focus on improving secretion and preventing aggregation in the Pichia pastoris expression system. The key products or services to be...
This Project Grant award from the National Human Genome Research Institute (NHGRI), funded under the Human Genome Research program (CFDA 93.172), aims to develop new strategies that leverage protein-protein interaction data to enhance the ability to infer proteomic changes from mRNA abundance measurements. The $435,406 award supports two key objectives: 1) Exploring the use of conceptual protein embeddings to capture protein network topology and sequence/structure information, to aid in...

A QUICK AND SIMPLIFIED METHOD (QUICKRIBO-MRNA) FOR ISOLATION OF RIBOSOME PROTECTED MRNA FRAGMENTS FOR TRANSLATOME IDENTIFICATION - THE GOAL OF THIS PROPOSAL IS TO ESTABLISH AND VALIDATE A NOVEL METHOD FOR THE ISOLATION OF RIBOSOME PROTECTED MRNA FOOTPRINTS FOR TRANSLATOME IDENTIFICATION. TRANSLATOME OR RIBOSOME PROFILING (RP), A DEEP SEQUENCING TECHNIQUE OF RIBOSOME-PROTECTED MRNA FOOTPRINTS, IS A POWERFUL METHOD THAT GIVES A "SNAPSHOT" OF ACTIVELY TRANSLATING MRNA. REVOLUTIONIZING THE CAPACITY TO CAPTURE EVERY STEP OF MRNA TRANSLATION AT SUB-CODON RESOLUTION, IT POTENTIALLY ALLOWS ONE TO MONITOR THE RATE AND LOCATION OF MRNA TRANSLATION IN THE CELL AND ANNOTATE THE NEW PROTEIN CODING SEQUENCES OF GENOMES. RP, THEREFORE, AFFORDS A VAST OPPORTUNITY TO EXPLORE AND MODEL COMPLEX CELLULAR PROCESSES IN REAL TIME. THIS METHODOLOGY HAS BEEN MINED EXTENSIVELY IN NUMEROUS DISEASES INCLUDING CANCER, IMMUNOLOGY AND NEUROLOGY. RP IDENTIFIED SEVERAL NEW MICRO-PEPTIDES AND PROTEIN FROM COVID MRNA, FURTHER EXPANDING ITS POTENTIAL AS A NOVEL TARGET-IDENTIFICATION METHOD. IN THIS CONTEXT, RP HAS EMERGED AS A POTENT METHOD TO IDENTIFY MRNA FRAMESHIFTING AND NOVEL ORFS, AND PROVIDING VALUABLE INSIGHTS FOR UNDERSTANDING FUNCTIONAL ELEMENTS OF THE GENOME, DISEASE PATHOGENESIS AND EVALUATION OF IMPACT TREATMENT IN THE CASE OF MRNA THERAPEUTICS AND CANCER THERAPY IN A GENE AND THE TISSUES SPECIFIC MANNER. HOWEVER, RP APPLICATIONS ARE STUNTED AND LIMITED TO SPECIALIZED LABS BECAUSE IT REQUIRES EXPERTISE, SPECIALIZED INSTRUMENTS AND TIME-CONSUMING - TAKING UP TO ~5 DAYS ON AN AVERAGE. IN TURN, THIS AFFECTS THE COST, QUALITY OF THE FINAL DATA AND THEREBY OBSCURING THE MRNA TRANSLATIONAL LANDSCAPE. GIVEN THE POWER AND POTENTIAL FOR WIDESPREAD USE, THERE IS AN URGENT AND UNMET NEED FOR ALTERNATIVE/IMPROVED RP TECHNOLOGY SIMILAR TO RNA PURIFICATION METHODS WHICH ARE LESS TIME CONSUMING, FREE OF ARTIFACTS AND INEXPENSIVE. IN PHASE-I APPLICATION, WE PROPOSED TWO SPECIFIC AIMS TO REFINE THE QUICKRIBO-MRNA METHOD, VALIDATE AND COMPARE IT WITH CURRENT RP METHODS TO ESTABLISH ITS EFFICACY. IN AIM-1 WE WILL ESTABLISH AND VALIDATE THE QUICKRIBO-MRNA METHODOLOGY IN VARIOUS CONDITIONS AND CELL TYPES IN OBTAINING UNIFORM RIBOSOME PROTECTED MRNA FRAGMENTS WITH IMPROVED PERCENT READ MAPPING TO CODING SEQUENCES. IN AIM-2 WE WILL COMPARE THE EFFICACY OF QUICKRIBO-MRNA WITH KNOWN RIBOSOME PROFILING TECHNOLOGIES. WE BELIEVE THAT PHASE-I PROPOSAL WILL PROVIDE A BENCHMARK FOR PHASE II, WHICH CAN STREAMLINE THE QUICKRIBO-MRNA METHOD FOR PERFORMING RIBOSOME PROFILING WITH HIGH REPRODUCIBILITY AND EFFICIENCY. IN THE END RP WILL BE DONE PROFICIENTLY IN THE SIMPLEST WAY WITH LESS TIME, INSTRUMENTATION AND EXPERTISE TO IDENTIFY GENE "EXPRESSION WITH READING FRAMES AND TRANSLATION EFFICIENCY" BEFORE MAKING ANY CONCLUSIONS ENTIRELY BASED ON RNA-GENE "EXPRESSION PROFILE".

Posted 9/14/21, 12:00 AM